Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, China.
Immunotherapy. 2023 Feb;15(3):209-220. doi: 10.2217/imt-2022-0028. Epub 2023 Jan 30.
This study aimed to explore the association of immune-related adverse events (irAEs) with efficacy in advanced non-small-cell lung cancer (NSCLC). A literature search was conducted under preselected criteria. Primary outcomes were hazard ratio (HR) and 95% CI of irAEs on objective response rate, overall survival (OS) and progression-free survival (PFS). 35 studies covering 8435 patients with advanced NSCLC were included. Patients with irAEs exhibited significantly longer PFS and OS (for PFS, HR: 0.481; 95% CI: 0.370-0.568; p < 0.001 and for OS, HR: 0.470; 95% CI: 0.410-0.539; p < 0.001), and also showed significantly higher objective response rate compared with those without irAEs (pooled OR: 0.023 [95% CI: 0.009-0.590]). This meta-analysis showed that irAEs were associated with efficacy for advanced NSCLC.
本研究旨在探讨免疫相关不良事件（irAEs）与晚期非小细胞肺癌（NSCLC）疗效的关系。根据预先设定的标准进行文献检索。主要结局指标为 irAEs 对客观缓解率（ORR）、总生存期（OS）和无进展生存期（PFS）的危害比（HR）和 95%置信区间（CI）。纳入了 35 项涵盖 8435 例晚期 NSCLC 患者的研究。发生 irAEs 的患者的 PFS 和 OS 明显更长（对于 PFS，HR：0.481；95%CI：0.370-0.568；p<0.001；对于 OS，HR：0.470；95%CI：0.410-0.539；p<0.001），并且与无 irAEs 的患者相比，ORR 也显著更高（合并 OR：0.023[95%CI：0.009-0.590]）。这项荟萃分析表明，irAEs 与晚期 NSCLC 的疗效相关。
